

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3268.1005-001	APPLICATION NO. 10/729,427
O I P E INFORMATION DISCLOSURE CITATION IN AN APPLICATION MAY 26 2004 April 30, 2004 PATENT & TRADEMARK OFFICE Use several sheets if necessary)			FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>	FILING DATE December 5, 2003
			EXAMINER Not Yet Assigned	CONFIRMATION NO. 8405
				GROUP 1614

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
MG	AA	5,741,802	04-21-1998	Kem, <i>et al.</i>
	AB	5,902,814	05-11-1999	Gordon, <i>et al.</i>
	AC	5,977,144	11-02-1999	Meyer, <i>et al.</i>
	AD	5,998,429	12-07-1999	Macor, <i>et al.</i>
	AE	6,054,434	04-25-2000	Kropp, <i>et al.</i>
	AF	6,110,914	08-29-2000	Phillips, <i>et al.</i>
	AG	6,232,319 B1	05-15-2001	Marazano, <i>et al.</i>
	AH	US 2002/0040035 A1	04-04-2002	Myers, <i>et al.</i>
	AI	6,369,224 B1	04-09-2002	Phillips, <i>et al.</i>
	AJ	6,407,095 B1	06-18-2002	Lochead, <i>et al.</i>
	AK	6,432,975 B1	08-13-2002	Schmitt, <i>et al.</i>
	AA2	6,441,049 B2	08-27-2002	Reitz, <i>et al.</i>
	AB2	6,479,172 B2	11-12-2002	Hu, <i>et al.</i>
	AC2	6,479,510 B2	11-12-2002	Myers, <i>et al.</i>
	AD2	6,486,172 B2	11-26-2002	Myers, <i>et al.</i>
	AE2	6,492,386 B2	12-10-2002	Myers, <i>et al.</i>
	AF2	6,500,840 B2	12-31-2002	Myers, <i>et al.</i>
	AG2	6,538,003 B1	03-25-2003	Galli, <i>et al.</i>
	AH2	6,562,816 B2	05-13-2003	Wishka, <i>et al.</i>
	AI2	6,569,865 B2	05-27-2003	Eifion
	AJ2	US 2003/0105089 A1	06-05-2003	Wishka, <i>et al.</i>
	AK2	US 2003/0119837 A1	06-26-2003	O'Neill, <i>et al.</i>
	AA3	US 2003/0130305 A1	07-10-2003	Walker, <i>et al.</i>
	AB3	6,599,916 B2	07-29-2003	Myers, <i>et al.</i>
▼	AC3	US 2003/0149065 A1	08-07-2003	Loch III, <i>et al.</i>
MG	AD3	US 2003/0153595 A1	08-14-2003	Walker, <i>et al.</i>

EXAMINER /Michel Graffeo/	DATE CONSIDERED 02/12/2007
------------------------------	-------------------------------

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3268.1005-001	APPLICATION NO. 10/729,427
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>	FILING DATE December 5, 2003
April 30, 2004 (Use several sheets if necessary)			EXAMINER Not Yet Assigned	CONFIRMATION NO. 8405
				GROUP 1614

U.S. PATENT DOCUMENTS				
EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
MG	AE3	US 2003/0176416 A1	09-18-2003	Peters, <i>et al.</i>
	AF3	US 2003/0176702 A1	09-18-2003	Walker, <i>et al.</i>
	AG3	6,635,645 B1	10-21-2003	Lochead, <i>et al.</i>
	AH3	6,552,012	04-22-2003	Peters, <i>et al.</i>
▼	AI3	6,492,385	12-10-2002	Myers, <i>et al.</i>
MG	AJ3	US 2002/0086871 A1	07-04-2002	O'Neill, <i>et al.</i>

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
MG	AL	WO 01/85727 A1	11-15-2001	Novartis AG	
	AM	WO 02/44176 A1	06-06-2002	Neurosearch A/S	
	AN	WO 02/057275 A1	07-25-2002	University of Kentucky Research Foundation	
	AO	WO 03/032897 A2	04-25-2003	Astrazeneca AB	
▼	AP	WO 03/078431 A1	09-25-2003	Joachim Luithle, <i>et al.</i>	X
MG	AQ	JP 2002-030084 (Patent Abstract)	01-29-2002	Mitsubishi Pharma Corp.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
MG	AR	Wang, <i>et al.</i> , "Nicotinic acetylcholine receptor $\alpha$ 7 subunit is an essential regulator of inflammation," <i>Nature</i> , pp. 1-4 (2002).
	AS	Borovikova, <i>et al.</i> , "Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin," <i>Nature</i> , 405: 458-462 (2000).
	AT	Tracey, Kevin J., <i>et al.</i> , "Mind over immunity," <i>FASEB J.</i> , 15(9): 1575-1576 (2001).
▼	AU	Meyer, Edwin M., <i>et al.</i> , "3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat $\alpha$ 7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner," <i>Brain Res.</i> , 768(1-2): 49-56 (1997).

EXAMINER /Michel Graffeo/	DATE CONSIDERED 02/12/2007
------------------------------	-------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3268.1005-001	APPLICATION NO. 10/729,427
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		FIRST NAMED INVENTOR Kevin J. Tracey, <i>et al.</i>	FILING DATE December 5, 2003
April 30, 2004 (Use several sheets if necessary)		EXAMINER Not Yet Assigned	CONFIRMATION NO. 8405
			GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
MG	AV	Alkondon, M., <i>et al.</i> , "Choline is a Selective Agonist of $\alpha$ 7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons," <i>Eur. J. Neurosci.</i> , 9(12): 2734-2742 (1997).	
	AW	Levin, E.D., <i>et al.</i> , "AR-R17779, an $\alpha$ 7 nicotinic agonist, improves learning and memory in rats," <i>Behav. Pharmacol.</i> , 10(6-7): 675-680 (1999).	
	AX	Kem, William R. "The brain $\alpha$ 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21)," <i>Behav. Brain Res.</i> , 113: 169-181 (2000).	
	AY	Broad, Lisa M., <i>et al.</i> , "PSAB-OFP, a selective $\alpha$ 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT <sub>3</sub> receptor," <i>Eur. J. Pharmacol.</i> , 452(2): 137-144 (2002).	
	AZ	Francis, Michael M., <i>et al.</i> , "Specific Activation of the $\alpha$ 7 Nicotinic Acetylcholine Receptor by a Quaternary Analog of Cocaine," <i>Mol. Pharmacol.</i> , 60(1): 71-79 (2001).	
MG	AR2	Mullen, George, <i>et al.</i> , "(-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a Conformationally Restricted Analogue of Acetylcholine, Is a Highly Selective Full Agonist at the $\alpha$ 7 Nicotinic Acetylcholine Receptor," <i>J. Med. Chem.</i> , 43(22): 4045-4050 (2000).	

EXAMINER <i>/Michel Graffeo/</i>	DATE CONSIDERED 02/12/2007
-------------------------------------	-------------------------------